Dolutegravir Expanded Access Study

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 14, 2012

Primary Completion Date

September 23, 2016

Study Completion Date

September 23, 2016

Conditions
Infection, Human Immunodeficiency VirusHIV Infections
Interventions
DRUG

Dolutegravir

Eligible patients will receive DTG 50 mg given orally BID

Trial Locations (74)

1000

GSK Investigational Site, Brussels

1057

GSK Investigational Site, The Bronx

2000

GSK Investigational Site, Antwerp

2006

GSK Investigational Site, Porto Alegre

4000

GSK Investigational Site, Liège

10011

GSK Investigational Site, New York

13274

GSK Investigational Site, Marseille

16128

GSK Investigational Site, Genoa

16132

GSK Investigational Site, Genoa

17604

GSK Investigational Site, Lancaster

19107

GSK Investigational Site, Philadelphia

20127

GSK Investigational Site, Milan

23538

GSK Investigational Site, Lübeck

27100

GSK Investigational Site, Pavia

30122

GSK Investigational Site, Venezia

30322

GSK Investigational Site, Atlanta

32803

GSK Investigational Site, Orlando

32960

GSK Investigational Site, Vero Beach

33076

GSK Investigational Site, Bordeaux

33311

GSK Investigational Site, Fort Lauderdale

33316

GSK Investigational Site, Fort Lauderdale

33701

GSK Investigational Site, St. Petersburg

41124

GSK Investigational Site, Modena

49090

GSK Investigational Site, Osnabrück

50011

GSK Investigational Site, Bagno A Ripoli (FI)

50134

GSK Investigational Site, Florence

50674

GSK Investigational Site, Cologne

53127

GSK Investigational Site, Bonn

60596

GSK Investigational Site, Frankfurt am Main

60612

GSK Investigational Site, Chicago

60613

GSK Investigational Site, Chicago

60657

GSK Investigational Site, Chicago

63139

GSK Investigational Site, St Louis

66606

GSK Investigational Site, Topeka

68161

GSK Investigational Site, Mannheim

68198

GSK Investigational Site, Omaha

70197

GSK Investigational Site, Stuttgart

75012

GSK Investigational Site, Paris

75013

GSK Investigational Site, Paris

75015

GSK Investigational Site, Paris

75204

GSK Investigational Site, Dallas

75475

GSK Investigational Site, Paris

75679

GSK Investigational Site, Paris

75877

GSK Investigational Site, Paris

75970

GSK Investigational Site, Paris

77004

GSK Investigational Site, Houston

77098

GSK Investigational Site, Houston

78705

GSK Investigational Site, Austin

79106

GSK Investigational Site, Freiburg im Breisgau

80218

GSK Investigational Site, Denver

85012

GSK Investigational Site, Phoenix

94115

GSK Investigational Site, San Francisco

94275

GSK Investigational Site, Le Kremlin-Bicêtre

27599-7215

GSK Investigational Site, Chapel Hill

A-8020

GSK Investigational Site, Graz

A-4020

GSK Investigational Site, Linz

A-1140

GSK Investigational Site, Vienna

22410-906

GSK Investigational Site, Ipanema

27910-210

GSK Investigational Site, Macaé

04121-000

GSK Investigational Site, São Paulo

60455-610

GSK Investigational Site, Fortaleza

57035-110

GSK Investigational Site, Maceió

14048-900

GSK Investigational Site, Ribeirão Preto

20520-054

GSK Investigational Site, Rio de Janeiro

20725-090

GSK Investigational Site, Rio de Janeiro

21040-900

GSK Investigational Site, Rio de Janeiro

01246-000

GSK Investigational Site, São Paulo

29020-020

GSK Investigational Site, Vittoria

V6Z 1Y6

GSK Investigational Site, Vancouver

L8N3Z5

GSK Investigational Site, Hamilton

M5G 1K2

GSK Investigational Site, Toronto

H2L 4P9

GSK Investigational Site, Montreal

06202

GSK Investigational Site, Nice

71-455

GSK Investigational Site, Szczecin

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY